跳转至内容
Merck
CN
所有图片(1)

主要文件

MAB9012

Sigma-Aldrich

抗-冠状病毒抗体,OC-43菌株,克隆541-8F

clone 541-8F, Chemicon®, from mouse

登录查看公司和协议定价


About This Item

UNSPSC代码:
12352203
eCl@ss:
32160702
NACRES:
NA.41

生物来源

mouse

质量水平

抗体形式

purified immunoglobulin

抗体产品类型

primary antibodies

克隆

541-8F, monoclonal

种属反应性

human

制造商/商品名称

Chemicon®

技术

immunofluorescence: suitable

运输

wet ice

特异性

冠状病毒。

免疫原

表位:OC-43株

应用

IFA。 最终工作稀释度必须由最终用户确定。
抗冠状病毒抗体,OC-43株,克隆541-8F可检测冠状病毒水平,&已发布&验证可用于IF。
研究子类别
传染病 - 病毒
研究类别
传染病

外形

形式:纯化
纯化的免疫球蛋白。提供在pH 7.4的PBS缓冲液中。含0.1%叠氮化钠和载体蛋白。

储存及稳定性

自接收之日起,在2-8°C下保存长达6个月。

法律信息

CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany

免责声明

除非我们的目录或产品随附的其他公司文件中另有说明,否则我们的产品预期仅用于研究用途,不得用于任何其他目的,包括但不限于未经授权的商业用途、体外诊断用途、离体或体内治疗用途或对人类或动物的任何类型的消费或应用。

未找到合适的产品?  

试试我们的产品选型工具.

储存分类代码

10 - Combustible liquids

WGK

WGK 2

闪点(°F)

Not applicable

闪点(°C)

Not applicable


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Layla Pires et al.
Scientific reports, 12(1), 14438-14438 (2022-08-25)
The lack of therapeutic options to fight Covid-19 has contributed to the current global pandemic. Despite the emergence of effective vaccines, development of broad-spectrum antiviral treatment remains a significant challenge, in which antimicrobial photodynamic therapy (aPDT) may play a role
Kai-Wen Cheng et al.
Cells, 10(11) (2021-11-28)
Human coronavirus (HCoV) similar to other viruses rely on host cell machinery for both replication and to spread. The p97/VCP ATPase is associated with diverse pathways that may favor HCoV replication. In this study, we assessed the role of p97
Peifang Xie et al.
Phytomedicine : international journal of phytotherapy and phytopharmacology, 93, 153808-153808 (2021-11-10)
Qingwenjiere Mixture (QJM) is a traditional Chinese medicine (TCM) that has been shown to have remarkable clinical efficacy against COVID-19. However, little is known about the antiviral and anti-inflammatory activities of QJM against a wider range of human coronavirus (HCoV)
Yanmei Hu et al.
Journal of medical virology, 94(5), 2188-2200 (2022-01-27)
Brilacidin, a mimetic of host defense peptides (HDPs), is currently in Phase 2 clinical trial as an antibiotic drug candidate. A recent study reported that brilacidin has antiviral activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by inactivating the
Ayan Kumar Ghosh et al.
ACS infectious diseases, 7(7), 1985-1995 (2021-03-31)
As the toll of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic continues, efforts are ongoing to identify new agents and repurpose safe drugs for its treatment. Antimalarial peroxides have reported antiviral and anticancer activities. Here, we evaluated the

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门